Michael Makris/LinkedIn
Apr 3, 2026, 15:51
Michael Makris: Approved but Unavailable Hemophilia B Gene Therapy Remains Out of Reach
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn:
”If you are hoping to have gene therapy for hemophilia B you will have to wait, as currently there is no product available for use outside China.
Hemgenix is the only FDA/EMA approved gene therapy that is commercially available, but the company making it has announced that they do not have any product due to a manufacturing issue. They stress that this is not a safety issue.
The Chinese product is only approved for use in China, and it is at least theoretically possible to travel to have the infusion in Shanghai.”
Other posts featuring Michael Makris on Hemostasis Today.
-
May 28, 2026, 12:57Ahmed Kardousha: Protecting Growth and Fertility in Transfusion-Dependent β-Thalassemia
-
May 28, 2026, 12:36Kabilan K L: Key Nursing Considerations for Abciximab Therapy
-
May 28, 2026, 12:17Astha Thakkar: Practical Approaches to Platelet Thresholds in ITP
-
May 28, 2026, 09:16Maxime Dely: The Human Connection Behind Stem Cell Donation
-
May 28, 2026, 09:15Heghine Khachatryan: Maternal Health Begins With Recognizing Iron Deficiency Early
-
May 28, 2026, 09:15Alejandro González Veliz: Why Cardiovascular Prevention Matters More Than Intervention
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly